Univariable and multivariable Cox regression of recurrence-free survival
| Variable | Univariable | Multivariable | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender | ||||
| Female | 1 | 0.7880 | ||
| Male | 1.10 (0.55 to 2.19) | |||
| Age (years) | ||||
| ≤60 | 1 | 0.1136 | ||
| >60 | 1.69 (0.88 to 3.25) | |||
| Breslow thickness (mm) | ||||
| <1.0 | 1 | 0.3058 | ||
| 1.0–2.0 | 0.42 (0.14 to 1.27) | |||
| 2.1–4.0 | 0.42 (0.15 to 1.20) | |||
| >4.0 | 0.35 (0.11 to 1.11) | |||
| Mitoses | ||||
| 0/<1 | 1 | 0.1187 | ||
| 1–3 | 0.10 (0.01 to 0.87) | |||
| 4–10 | 0.11 (0.01 to 0.97) | |||
| >10 | 0.06 (0.01 to 0.61) | |||
| BRAF | ||||
| NonV600E/WT | 1 | 0.5124 | ||
| V600E | 1.27 (0.63 to 2.56) | |||
| Ulceration | ||||
| No | 1 | 0.5294 | ||
| Yes | 1.27 (0.60 to 2.67) | |||
| Primary site | ||||
| Cutaneous | 1 | 0.4699 | ||
| Acral | 0.63 (0.09 to 4.64) | |||
| Occult | 0.54 (0.19 to 1.52) | |||
| Stage III | ||||
| A/B | 1 | 0.0375 | 1 | 0.5237 |
| C/D | 2.08 (1.04 to 4.15) | 1.29 (0.59 to 2.82) | ||
| Stage III detail | ||||
| Nodal only | 1 | 0.5942 | ||
| ITM only | 0.66 (0.23 to 1.88) | |||
| Both nodal/ITM | 0.49 (0.07 to 3.56) | |||
| Time to stage III | ||||
| Concurrent | 1 | 0.3919 | ||
| 3–6 months | 2.19 (0.63 to 7.67) | |||
| 6 months–1 year | 1.30 (0.29 to 5.74) | |||
| 1–2 years | 1.10 (0.36 to 3.35) | |||
| >2 years | 2.14 (0.94 to 4.85) | |||
| LN status | ||||
| Microscopic | 1 | 0.2765 | ||
| Macroscopic | 1.48 (0.73 to 3.02) | |||
| CLND performed | ||||
| No | 1 | 0.0206 | 1 | 0.0267 |
| Yes | 2.69 (1.16 to 6.20) | 2.85 (1.13 to 7.19) | ||
| CLND site | ||||
| Neck | 1 | 0.0029 | ||
| Axilla | 0.51 (0.21 to 1.22) | |||
| Groin | 0.44 (0.14 to 1.40) | |||
| Multiple | 10.98 (1.98 to 60.94) | |||
| Number of nodes | ||||
| 0–1 | 1 | 0.0021 | ||
| 2–3 | 1.12 (0.38 to 3.36) | |||
| ≥4 | 4.20 (1.76 to 10.04) | |||
| Extranodal spread | ||||
| No | 1 | 0.1794 | ||
| Yes | 1.70 (0.78 to 3.68) | |||
| White cell count | ||||
| Below median | 1 | 0.4716 | ||
| Above median | 1.29 (0.65 to 2.55) | |||
| Neutrophil | ||||
| Below median | 1 | 0.4531 | ||
| Above median | 0.77 (0.38 to 1.53) | |||
| Lymphocyte | ||||
| Below median | 1 | 0.2501 | ||
| Above median | 0.67 (0.34 to 1.33) | |||
| Neutro:lympho ratio | ||||
| Below median | 1 | 0.5433 | ||
| Above median | 0.81 (0.41 to 1.61) | |||
| Monocyte | ||||
| Below median | 1 | 0.8997 | ||
| Above median | 0.96 (0.48 to 1.90) | |||
| Eosinophil | ||||
| Below median | 1 | 0.6674 | ||
| Above median | 0.86 (0.43 to 1.73) | |||
| Basophil | ||||
| Below median | 1 | 0.9861 | ||
| Above median | 0.99 (0.49 to 2.00) | |||
| CD8+ T cells (cells/mm2) | ||||
| Below median | 1 | 0.7760 | ||
| Above median | 1.10 (0.56 to 2.16) | |||
| CD39+CD103+PD-1+ % of CD8+ T cells | ||||
| Below median | 1 | 0.0097 | 1 | 0.0036 |
| Above median | 0.39 (0.19 to 0.79) | 0.32 (0.15 to 0.69) | ||
| CD39-CD103-PD-1 % of CD8+ T cells | ||||
| Below median | 1 | 0.1603 | ||
| Above median | 1.64 (0.82, 3.28) | |||
| CD8+ average distance to Mel | ||||
| Below median | 1 | 0.1171 | ||
| Above median | 0.53 (0.24 to 1.17) | |||
| CD39+CD103+PD-1+CD8+ average distance to Mel | ||||
| Below median | 1 | 0.2473 | ||
| Above median | 0.60 (0.26 to 1.42) | |||
| CD39-CD103-PD-1-CD8+ average distance to Mel | ||||
| Below median | 1 | 0.1311 | ||
| Above median | 0.54 (0.25 to 1.20) | |||
| %CD8+ >20 μm of Mel | ||||
| Below median | 1 | 0.4267 | ||
| Above median | 1.36 (0.64 to 2.91) | |||
| %CD39+CD103+PD-1+CD8+ >20 μm of Mel | ||||
| Below median | 1 | 0.6022 | ||
| Above median | 0.80 (0.35 to 1.85) | |||
| %CD39-CD103-PD-1-CD8+ >20 μm of Mel | ||||
| Below median | 1 | 0.6283 | ||
| Above median | 1.21 (0.56 to 2.62) | |||
| PD-L1 status (>1%) | ||||
| Negative | 1 | 0.5560 | ||
| Positive | 0.81 (0.41 to 1.63) | |||
CLND, completion lymph node dissection; Mel, melanoma.